| City University of New York (CUNY) | |
|---|---|
| 🏛️ | |
| Location | New York City, New York, USA |
| Type | Public Research University System |
| Founded | 1847 (as Free Academy) |
| Website | https://www.cuny.edu |
| Neurodegeneration Focus | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease |
| Key Facilities | Advanced Science Research Center, Hunter College Neuroscience Institute |
The City University of New York (CUNY) is the largest urban public university system in the United States, serving over 500,000 students across 25 colleges and institutions. Founded in 1847 as the Free Academy of the City of New York (now City College), CUNY has grown into a comprehensive academic system with significant research capabilities in neuroscience and neurodegenerative disease research[1].
CUNY's research programs in neurodegeneration are primarily conducted through its senior colleges, particularly The Graduate Center, Hunter College, Brooklyn College, and the Advanced Science Research Center (ASRC). These institutions contribute to understanding the mechanisms of neurodegenerative diseases and developing novel therapeutic approaches.
The City University of New York system traces its origins to 1847 when the Free Academy of the City of New York was established. Over its nearly 180-year history, CUNY has expanded from a single institution to a system of 25 colleges and institutions across New York City's five boroughs. The system includes:
The expansion of neuroscience research capabilities came particularly in the late 20th and early 21st centuries with the establishment of the Advanced Science Research Center in 2014, which houses state-of-the-art neuroscience research facilities.
CUNY researchers contribute significantly to understanding neurodegenerative diseases through multiple departments and centers:
Research on neural development, synaptic function, and neuroplasticity forms a core strength at CUNY. Investigators study:
Studies on protein aggregation, DNA repair mechanisms, and gene expression:
Bioinformatics approaches to identify disease biomarkers and therapeutic targets:
Clinical research on Alzheimer's disease, Parkinson's disease, and related disorders conducted through affiliated clinical facilities and collaborations with medical centers throughout New York City.
The CUNY ASRC, opened in 2014, serves as a hub for advanced research in neuroscience and other fields. Key features include:
Hunter College hosts a major neuroscience program focused on:
Research at Brooklyn College focuses on:
The College of Staten Island conducts research on:
CUNY researchers investigate multiple aspects of Alzheimer's disease:
Research programs focus on:
The ALS research program addresses:
Research includes:
CUNY houses several prominent researchers studying neurodegeneration:
CUNY offers comprehensive training opportunities in neuroscience and neurodegeneration:
CUNY maintains active collaborations with clinical institutions in New York City:
CUNY researchers participate in international research networks:
CUNY's neuroscience research has significant impact on the New York City area:
CUNY is pursuing several strategic initiatives in neurodegeneration research:
Robinson J, et al. Synaptic dysfunction in Alzheimer's disease: from mechanisms to therapy. Neuron. 2022. ↩︎
Chen X, et al. Tau propagation in Alzheimer's disease: mechanisms and therapeutic targets. Nat Rev Neurol. 2023. ↩︎ ↩︎
Li J, et al. Alpha-synuclein aggregation in Parkinson's disease: cellular mechanisms. Brain. 2022. ↩︎ ↩︎
Garcia C, et al. RNA metabolism in ALS: mechanisms and therapeutic implications. Nat Rev Neurol. 2022. ↩︎ ↩︎
Brown A, et al. Computational approaches to neurodegeneration biomarker discovery. Bioinformatics. 2022. ↩︎
Marcus J, et al. Amyloid-beta deposition in aging and Alzheimer's disease: neuroimaging findings. Neuroimage. 2022. ↩︎
Kumar P, et al. Neuroinflammation in neurodegenerative diseases: microglial activation. Brain Behav Immun. 2023. ↩︎
Clarke J, et al. TREM2 variants in Alzheimer's disease: mechanism and therapeutic targeting. Alzheimers Dement. 2022. ↩︎
Taylor M, et al. Blood-based biomarkers for Alzheimer's disease: current status. Alzheimers Res Ther. 2021. ↩︎
Anderson R, et al. Neuroimaging biomarkers in neurodegenerative disease: advances and challenges. Lancet Neurol. 2023. ↩︎
Smith K, et al. Precision medicine approaches in Alzheimer's disease. Nat Rev Drug Discov. 2023. ↩︎
Wang Y, et al. Dopaminergic neuron vulnerability in Parkinson's disease. Mov Disord. 2021. ↩︎
Martinez S, et al. Mitochondrial dysfunction in Parkinson's disease: therapeutic strategies. J Neural Transm. 2021. ↩︎
Johnson K, et al. Parkinson's disease genetics: LRRK2 and GBA in diverse populations. Neurology. 2023. ↩︎
Thompson D, et al. Gut-brain axis in Parkinson's disease: microbiome changes and clinical implications. Mov Disord. 2021. ↩︎
Williams G, et al. Huntington's disease: genetic modifiers and therapeutic approaches. J Huntingtons Dis. 2021. ↩︎
Hof P, et al. Neuropathology of Alzheimer's disease: Beyond plaques and tangles. Acta Neuropathol. 2021. ↩︎
Davis L, et al. Astrocyte reactivity in neurodegeneration: friend or foe?. Glia. 2023. ↩︎
White P, et al. Epigenetic modifications in Alzheimer's disease: diagnostic potential. Epigenomics. 2021. ↩︎
Lee H, et al. Autophagy impairment in neurodegenerative diseases. Cell Mol Neurobiol. 2022. ↩︎
Young B, et al. Exercise and cognitive function in neurodegeneration: mechanisms. Neurology. 2023. ↩︎